Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 7/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | SDHB | P21912 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22321581 | 0.90 | TRPV3 (0.42) | ADRB3TRPV3ADRB1ADRB2 | |
| SCHEMBL22321632 | 0.90 | TRPV3 (0.42) | ADRB3TRPV3ADRB1ADRB2 | |
| SCHEMBL22321580 | 0.90 | TRPV3 (0.42) | ADRB3TRPV3ADRB1ADRB2 | |
| SCHEMBL22337539 | 0.89 | KCNH2 (0.37) | KCNH2ADRB3TRPV3ADRB1ADRB2 | |
| SCHEMBL22337651 | 0.89 | KCNH2 (0.48) | KCNH2ADRB3TRPV3ADRB1ADRB2 | |
| SCHEMBL22337461 | 0.88 | KCNH2 (0.48) | KCNH2ADRB3TRPV3ADRB1ADRB2 | |
| SCHEMBL22337760 | 0.83 | FAAH (0.39) | KCNH2ADRB3ADRB1ADRB2 | |
| SCHEMBL22321567 | 0.81 | KCNH2 (0.44) | KCNH2TRPV3ADRB1ADRB2 | |
| SCHEMBL22321622 | 0.81 | KCNH2 (0.44) | KCNH2TRPV3ADRB1ADRB2 | |
| SCHEMBL22321569 | 0.81 | KCNH2 (0.44) | KCNH2TRPV3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | UNIV AMIENS PICARDIE JULES VERNE (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | QDPR, PNMT, CYP3A43 | KCNH2 404/4885ADRB3 26/4885TRPV3 221/4885 |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | QDPR, PNMT, CYP3A43 | KCNH2 529/4885ADRB3 39/4885TRPV3 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.